GlassScriptPhysician profile
Godwin H Dsouza
NPI 1619915295
$13,150.11
in general payments reported to CMS, 2019-2025
70 companies · $2,299 in 2025
The $2,299 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,183 · 2020: $1,131 · 2021: $1,903 · 2022: $1,928 · 2023: $1,643 · 2024: $2,063 · 2025: $2,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,005.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,223.50 | 2019-2025 | Linzess, Viberzi, Creon |
| Novo Nordisk INC | $1,185.85 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $758.19 | 2019-2025 | Mounjaro, Trulicity, Kisunla |
| Pfizer INC. | $647.47 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $642.78 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $621.90 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $492.58 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| E.R. Squibb & Sons, L.L.C. | $491.21 | 2019-2025 | Eliquis, Camzyos |
| Sumitomo Pharma America, INC. | $425.78 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $414.43 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $385.01 | 2019-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $380.52 | 2021-2025 | |
| Amgen INC. | $354.83 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Amarin Pharma, INC. | $349.89 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $349.23 | 2019-2022 |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Godwin Dsouza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.